Objective: Effect of a probiotic on the gut microbiome and peripheral immune function in healthy controls and relapsing-remitting multiple sclerosis (MS) patients. Methods: MS patients (N 5 9) and controls (N 5 13) were orally administered a probiotic containing Lactobacillus, Bifidobacterium, and Streptococcus twice-daily for two months. Blood and stool specimens were collected at baseline, after completion of the 2-month treatment, and 3 months after discontinuation of therapy. Frozen peripheral blood mononuclear cells (PBMCs) were used for immune cell profiling. Stool samples were used for 16S rRNA profiling and metabolomics. Results: Probiotic administration increased the abundance of several taxa known to be depleted in MS such as Lactobacillus. We found that probiotic use decreased the abundance of taxa previously associated with dysbiosis in MS, including Akkermansia and Blautia. Predictive metagenomic analysis revealed a decrease in the abundance of several KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways associated with altered gut microbiota function in MS patients, such as methane metabolism, following probiotic supplementation. At the immune level, probiotic administration induced an anti-inflammatory peripheral immune response characterized by decreased frequency of inflammatory monocytes, decreased mean fluorescence intensity (MFI) of CD80 on classical monocytes, as well as decreased human leukocyte antigen (HLA) D related MFI on dendritic cells. Probiotic administration was also associated with decreased expression of MS risk allele HLA-DQA1 in controls. Probiotic-induced increase in abundance of Lactobacillus and Bifidobacterium was associated with decreased expression of MS risk allele HLA.DPB1 in controls. Interpretation: Our results suggest that probiotics could have a synergistic effect with current MS therapies.
T he gut microbiome has been implicated in several autoimmune disorders, including inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis (MS). [1] [2] [3] [4] Studies in experimental autoimmune encephalomyelitis (EAE), the mouse model of MS, have shown that perturbation of the gut microbiota composition affects susceptibility to EAE. 5, 6 Others have shown that colonization of mice with Bacteroides fragilis ameliorates EAE 7 and that colonization of mice with segmented filamentous bacteria (SFB), a T helper (Th)17 inducer, exacerbates EAE. 8 Tryptophan-derived aryl hydrocarbon receptor ligands produced by intestinal commensals can reach the central nervous system (CNS) to modulate astrocyte function and suppress inflammation and neurodegeneration. 9 A recent study showed that the human gut-derived commensal Prevotella suppresses EAE in a human leukocyte antigen (HLA) class II transgenic mouse model. 10 Alterations in the gut microbiome of MS patients has been reported by a number of investigators. We have found increased Methanobrevibacter and decreased Butyricimonas in the gut microbiome of MS patients. 1 Others have reported dysbiosis in the gut microbiome of MS subjects. 3, 4 Recently, it was shown that high frequency of intestinal Th17 cells correlates with alterations in gut microbiota composition as well as increased disease activity in MS. 11 A twin study performed in discordant MS twins reported that the transfer of feces from the affected twin to germ-free mice induce more severe EAE symptoms than feces from the healthy twin. 12 Consistent with these fecal transfer experiment findings, another group observed that germ-free mice colonized with MS-derived feces develop more severe EAE symptoms than mice colonized with feces from healthy subjects. 13 These findings suggest that manipulation of the gut microbiome could potentially be beneficial to MS patients. The multistrain probiotic (probiotic LBS) contains eight bacteria and has been administered to animals and humans with good safety profile. Probiotic LBS has been shown to induce interleukin (IL)-10 1 and IL-10-dependent transforming growth factor beta-bearing regulatory cells in the gut of a mouse model of colitis. 14 Furthermore, LBS has been shown to promote an anti-inflammatory response in the gut of a mouse model of peanut allergy and diabetes. 15, 16 A recent study conducted in antiretroviral therapytreated human immunodeficiency virus type 1-positive patients reports an association between LBS administration and decreased T-cell activation in the peripheral blood and in gut-associated lymphoid tissue. 17 LBS immunomodulatory properties extend to the CNS system. For example, LBS has been shown to promote neuroprotection in a mouse model of traumatic spinal cord injury. 18 Another study reports that LBS administration was associated with decreased microglial cell activation as well as decreased CNS monocytes infiltration, leading to improved sickness behavior in a mouse model of liver inflammation. 19 In humans, LBS has been shown to be beneficial to patients with pouchitis, ulcerative colitis, and diabetes. [20] [21] [22] Little is known about the effect of LBS on peripheral immune function in humans. The goal of our study is to investigate the effect of LBS on the gut microbiome and peripheral immune function in healthy controls and MS patients.
Patients and Methods

Study population
Relapsing-remitting multiple sclerosis (RRMS) patients and healthy controls were recruited from the Partners MS Center at Brigham and Women's Hospital. RRMS subjects treated with glatiramer acetate (N 5 7), untreated (N 5 2), and healthy controls (N 5 13) were orally administered LBS twice-daily (total 3,600 billion colony-forming units [CFU]/day) for 2 months. Subjects' characteristics are shown in This study was approved by the Partners Human Research Committee, and all participants signed an informed consent before any data collection or study procedure. 
Sample Collection
Blood and stool specimens were collected before, at discontinuation of therapy, and 3 months thereafter (Fig 1) . Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density gradient centrifugation (Pharmacia LKB Biotechnology, Piscataway, NJ) and stored in liquid nitrogen until use. Stool samples were obtained from patients by providing them with stool containers. Subjects collected two samples at each time point produced at any time of day with no specific dietary restrictions. Collection containers were then placed in boxes with provided ice packs for immediate shipment to our laboratory by overnight delivery at a maintained temperature of 08C. On receipt of samples, they were frozen at 2808C until DNA extraction.
16S rRNA Microbial Community Profiling
Fecal DNA was isolated (MoBio PowerLyzer PowerSoil Kit), and the V4 region of the bacterial 16S rRNA gene was amplified using barcoded forward primers (515f, 926R) from the Earth Microbiome Project 23 and http://www.earthmicrobiome.
org/protocols-and-standards/16s/. Samples were sequenced by paired-end 250-base-pair (bp) reads at the Harvard Medical School Biopolymer Facility using the MiSeq platform (Illumina, San Diego, CA). Sequence quality was evaluated with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Median Phred quality scores were above Q30 for the first 230 bp, and above Q20 for the entire sequence for forward read; however, the median Phred Q scores for read 2 dropped below Q20 within the first 50 bases of the reverse read. Thus, we utilized only the forward read of 250 bases, corresponding to the V4 region of the microbial 16S rRNA. Downstream analysis was performed in QIIME (Qualitative Insights into Microbial Ecoloy). 24 Sequences were de-multiplexed and quality filtered in which reads are truncated if two consecutive bases fall below a quality score of Q20 (1% error), and reads that are <75% of full length are discarded. 23 Operational taxonomic units (OTUs) were picked using the open reference method sumaclust (http://metabarcoding.org/sumatra) and sortmeRNA. 25 Taxonomy is picked against the Greengenes 13.8 release database (http://greengenes.secondgenome.com) using a 97% similarity threshold. Alpha-diversity was calculated with the phylogentic diversity_whole_tree, Shannon diversity, richness metrics, and beta-diversity was calculated using weighted and unweighted UniFrac Distances.
Prediction Metagenomic
Metagenomic predictions were made using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) 26 and summarized as KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways.
Stool Metabolomics
Fecal samples were prepared for nuclear magnetic resonance (NMR) analysis by vortex mixing for 5 minutes 80mg of stool FIGURE 1: Study design flowchart. Blood and fecal samples were collected from healthy subjects (HC; n 5 13) and multiple sclerosis (MS) patients (n 5 9) before (baseline), at discontinuation of probiotic LBS (2-month visit), and 3 months thereafter (5-month visit). Bacteria DNA was extracted from feces samples obtained at all three time points and 16S rRNA sequencing was performed using Illumina MiSeq (Illumina, San Diego, CA).16S data were used to obtain predicted metagenomics by PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States). Feces samples were also used for stool metabolomics profiling at all three time points. Immune cells profiling was performed in healthy subjects and MS patients at all three time points by flow cytometry. Gene expression profiling was performed on peripheral monocytes and CD4 T cells from healthy controls and MS patients using a Nanostring immunology panel array and high-throughput eukaryotic digital gene expression RNA-Seq (RNA-DGE) respectively. PBMCs 5 peripheral blood mononuclear cells. H-NMR spectra were baseline adjusted by means of the simultaneous peak detection and baseline correction algorithm implemented in the baseline R package. 30 Briefly, the algorithm tries to iteratively locate peaks as consistent deviations from noise and interpolate over the spectra after peak removal. To each spectrum, a linear correction was then applied to make the points pertaining to the baseline randomly spread around zero. No manual alignment of signals was necessary, different to previous investigations. 31 Differences in water content among samples were taken into consideration by probabilistic quotient normalization, 32 applied to the entire spectra array.
Fluorescence-Activated Cell Sorting Analysis
Frozen PBMCs from all time points of 1 individual were processed and analyzed together to minimize batch-to-batch variability and allow for comparisons of mean fluorescence intensities (MFIs). Surface staining of PBMCs was performed as previously described. 33 Nonpurified CD4 T cells were activated with plate-bound anti-CD3 (5 lg/ml; BD Biosciences, San Jose, CA), soluble antihuman CD28 (1 lg/ml; BD Biosciences), and interleukin (IL)-2 (20ng/ml; R&D Systems, Minneapolis, MN) for 48 hours. CD4 T cells were stimulated with phorbol 12-myristate 13-acetate (50ng/ml; Sigma-Aldrich, St. Louis, MO), ionomycin (250ng/ml; Sigma), and Golgistop for 4 hours. CD4 T cells were stained with antihuman CD4 PE-CY7 and violet fluorescent reactive dye (VVD; Life Technologies, Carlsbad, CA), and then cells were fixed and permeabilized with BD fixation and permeabilization buffer and stained for IL17 PE, IL-10 APC, IFN-c FITC, and GMCSF-APC. Antibodies used for surface and intracellular staining of PBMCs are listed in the table below. Efluor 506 was obtained from BD Biosciences. All antibodies were titrated to obtain optimal signal-to-noise ratio. Samples were acquired using a BD LSR II flow cytometer (BD BioscienceS) and analyzed using FlowJo software (TreeStar, Inc., Ashland, OR). 
Gene Expression Studies
Monocytes and CD4 T cells were sorted from PBMCs of healthy controls (N 5 9 and N 5 7, respectively) and MS patients (N 5 7 and N 5 6, respectively) using the Miltenyi Biotec (Bergisch Gladbach, Germany) positive selection kit. Purified monocytes were treated with tumor necrosis factor alpha for 4 hours, after which they were lysed and the expression of immune genes were analyzed using a Nanostring array ANNALS of Neurology (nCounter, Gene expression code set, Human immunology kit) as previously described. 33 Purified CD4 T cells were activated with plate-bound anti-CD3 (5 lg/ml; BD Pharmingen), soluble antihuman CD28 (1 lg/ml; BD Pharmingen), and IL-2 (20ng/ ml; R&D Systems). After 48 hours, CD4 T cells were stained with 7-aminoactinomycin D viability dye to sort for viable CD4 T cells. Total RNA was extracted from viable T cells using the micro RNAeasy kit (Qiagen, Hilden, Germany), and RNA samples were submitted to the Broad Technology Labs for high-throughput eukaryotic digital gene expression RNA sequencing (RNA-Seq).
Statistical Analyses
Statistical differences for alpha and beta diversities were calculated with PRISM software (version 7.0; GraphPad Software Inc., La Jolla, CA) using paired one-way analysis of variance (ANOVA) with the Tukey post-test to assess significance at the 0.05 level and correct for multiple comparisons. Differences in beta-diversity visualized on the principal coordinate analysis (PCoA) plots were calculated with the ADONIS test at 999 permutations 34 using the R vegan package. 35 For Nanostring, fluorescence-activated cell sorting (FACS), stool metabolomics, compositional differences in taxonomic abundance, and predicted metagenome studies, we assessed the change between time points in the healthy controls and MS patients using the Wilcoxon signed-rank test. For this analysis, each pair of time points was compared, and the two groups were treated separately. To assess whether the change in one of the outcome measures was associated with the change in another outcome measure, we calculated the relevant change for both measures and compared them using Spearman's correlation coefficient. False discovery rate (FDR) was calculated using R software and the p. adjust function from the stats package.
Results
Product Tolerability and Safety
All study participants were greater than 90% compliant with probiotic supplementation. Patients were given the exact number of LBS sachets needed for the duration of the study, and compliance was monitored by asking patients to return back unused sachets. No serious adverse reactions were reported by the patients or identified by the clinicians. None of the patients experienced a relapse during or after probiotic supplementation.
Administration of Probiotic LBS Is Associated With Changes in the Structure and Composition of the Gut Microbiome in Healthy Controls and MS Subjects
To assess for temporal fluctuations in the gut microbiota composition, each subject provided two stool samples around 2 to 7 days apart at baseline, ON LBS and OFF LBS (six stool samples in total per subject). We compared the 16S profile of the paired stool samples for each time point using the ADONIS test of clustering and found no difference in their community structure in both controls and MS patients (p > 0.05 for all paired stool samples in both groups). Given that the temporal fluctuations in the gut microbiota composition were negligible, from here on, we merged the gut microbiome findings from the paired stool samples at each time point.
To assess for overall differences in microbial community structure in MS patients and controls, we calculated measures of alpha-and beta-diversity. Alpha diversity is a measurement of the ecological diversity within a given sample (ie, types of microbial species in a microbiota sample), whereas beta-diversity compares the bacterial composition between samples (ie, whether the microbial species are similar between microbiota samples). Shannon Index, an alpha-diversity measurement of both richness (number of species present) and evenness (whether there are predominant and rare species or equal representation of all species), was measured at multiple sequencing depths using rarefaction curves (Fig 2A) . We found that administration of LBS was associated with decreased alpha-diversity in healthy controls (Fig 2B) . No change in alpha-diversity was observed in MS subjects following LBS administration (Fig 2B) .
To determine whether overall microbial community structure was different among the three time points, we calculated differences in beta-diversity using the unweighted and weighted UniFrac metric and visualized the communities by PCoA. LBS administration significantly changed the overall microbial community structure in controls, as assessed by the ADONIS test for clustering of weighted UniFrac distances (p 5 0.048; Fig 2C) . We observed a similar trend in MS patients (p 5 0.10; Fig 2C) . The overall microbial community structure shifted back to baseline level following discontinuation of LBS in controls and MS patients (p 5 0.58 and p 5 0.54, respectively; Fig 2C) . No shift was observed with unweighted UniFrac distances, which measures the presence versus absence of the microbiota, likely attributed to the fact that taxa closely related to the strains within LBS are known to inhabit the gut, albeit at lower levels ( Fig  2D) . We next computed UniFrac distances for each subject, comparing baseline, ON LBS, and OFF LBS microbiota samples (Fig 2E) . Baseline compared to ON LBS and OFF LBS compared to ON LBS had higher weighted UniFrac distances than comparing baseline to OFF LBS (paired one-way ANOVA with Tukey's posttest), further suggesting that the individual microbiota compositions resembled their starting microbiota before treatment.
Consistent with these findings, we observed a change in the relative abundance of several genera following LBS supplementation in both controls and MS patients (Fig 3A) . We noted an increase in the relative abundance of several OTUs following LBS supplementation with enriched taxa predominated by Lactobacillus, Streptococcus, and Bifidobacterium (p < 0.05; Fig 3B) . We performed open reference OTU picking; thus, referencebased OTUs number and new reference (NR) OTUs unique to this study are listed in parentheses in Figure  3B .
Of note, previous studies have reported decreased abundance of Lactobacillus genera in MS patients. 4 Furthermore, a recent study reported that supplementation of MS patients with a cocktail of three Lactobacillus species and one Bifidobacterium species was associated with improved Expanded Disability Status Scale (EDSS) score as well as decreased depression and stress. 36 Others studies conducted in the EAE mouse model have demonstrated that administration of a cocktail of Lactobacillus species and/or Bifidobacterium species either before or after EAE induction ameliorate EAE. 37, 38 Hence, these studies suggest that increased in the relative abundance of Lactobacillus and Bifidobacterium taxa following LBS supplementation could be beneficial to MS patients. Following LBS administration, we observed an increase in relative abundance of family Veillonellaceae in controls (Fig 3B) and genus Collinsela (Fig 3C) , two taxa that are depleted in the gut of MS patients. LBS supplementation was also associated with a decrease in abundance of taxa that have been reported to be elevated in the gut of MS patients, including genera Akkermansia FIGURE 2: LBS effect on alpha and beta diversity of the gut microbiome. Rarefaction curves were calculated at multiple sequence depths on the MiSeq platform for Shannon entropy to compare differences in alpha-diversity at the indicated time points in (A) healthy controls (HC; n 5 13) and multiple sclerosis (MS) patients (n 5 9). Shannon index was also measured at a depth of 10,000 reads in (B) healthy controls and MS patients at the indicated time points determined by paired one-way analysis of variance (ANOVA) with Tukey's post-test, *p < 0.05. Principal coordinate analysis of weighted and unweighted UniFrac distances colored according to time points in (C,D) healthy controls and MS patients. (E) Average individual UniFrac distances calculated per subject assessed by paired one-way ANOVA with Tukey's post-test, *p < 0.05; **p < 0.01; #p < 0.1. PC 5 principal component.
(Th1 inducer), Blautia, and Dorea (Fig 3B,C) . We also observed a decrease in relative abundance of B. adolescentis (Th17 inducer), following LBS supplementation in controls and MS patients (Fig 3C) . The relative abundance of most of these OTUs returned to baseline levels following discontinuation of LBS (Fig 3B,C) . Thus, LBS 
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Functional Analysis of Gut Microbiota
We used PICRUSt to assess the functional content of the microbiota based on the 16S data. The abundance of several KEGG pathways was decreased in both controls and MS patients following LBS administration, including pathways related to Metabolism, Cellular Processes, Environmental Information and Processing, and Organismal Systems (p < 0.05; Fig 4A) . ABC transporters, Carbon fixation pathways in prokaryotes, Porphyrin and chlorophyll metabolism, and Sporulation are four KEGG pathways that have been reported to be increased in MS patients. 4 Abundance of these four pathways was reduced following LBS supplementation (p < 0.05; Fig 4A) . Methane metabolism is another pathway whose abundance was reduced following administration of LBS (p < 0.05; Fig 4A) . Methane is metabolized by methanogens, and we have previously reported increased abundance of a methanogen, Methanobrevibacter smithii, in MS patients. Hence, these findings suggest that LBS can reverse MS-related alterations in gut microbiota function. Next, we performed stool metabolomics profiling in controls and MS patients at all three time points. We noted increased concentration of uracil (p 5 0.006), adenosine monophosphate (p 5 0.027), hypoxanthine (p 5 0.040), and xanthine (p 5 0.017) following LBS supplementation in controls (Fig 4B) . We observed an increased 2-oxoglutarate level (p 5 0.040) following discontinuation of LBS in controls (Fig 4B) . In MS patients, we noted and increased level of 2-oxoglutarate (p 5 0.039) following LBS administration (Fig 4B) . We also found a decreased 3-hydroxyvalerate level (p 5 0.027) following LBS administration in MS patients (Fig 4B) . We observed an increased level of 3-methyl-oxovalerate (p 5 0.008), citrate (p 5 0.023), nicotinate (p 5 0.039), and alphaketoisovalerate (p 5 0.016) following LBS discontinuation in MS patients (Fig 4B) . We then investigated potential associations between gut microbiota and metabolites changes. We correlated microbial abundance with a set of metabolites whose concentration were significantly changed following LBS administration. In controls, we found a positive correlation between two Ruminococcaceae OTUs (187225 and 36378) and uracil levels following LBS administration (Fig 4C) . We also observed a positive correlation between Lactobacillus OTU 304724 and hypoxanthine concentration in controls (Fig 4C) . In MS patients, we found an association between increased in the relative abundance of the following four Lactobacillus OTUs (288784, 134726, 4414261, and 4429553) and adenosine monophosphate (Fig 4D) . We also observed a positive correlation between Streptococcus NROTU 985 and adenosine monophosphate in MS patients (Fig 4D) . We observed a trend toward a negative association between level of Bifidobacterium OTU 1142029 and hypoxanthine concentration in MS patients (Fig 4D) . We also found a trend toward a negative association between two Lactobacillus OTUs (288784 and 4429553) and hydroxyvalerate following LBS administration in MS (Fig 4D) . Thus, changes in the gut microbiota composition following LBS administration were associated with changes in stool metabolomics profile in controls and MS.
Changes in T-Cell Frequencies in Peripheral Blood
PBMCs were isolated from blood samples at all three time points and subsequently used for immune cell profiling by flow cytometry. Given previous reports of increased latencyassociated peptide (LAP) and IL10 Fig 5C) . Subsequently, we evaluated the frequencies of CD4 1 and CD8 1 T cells. We found a trend toward increased in frequency of effector memory CD8 T cells following probiotic supplementation in MS patients (p 5 0.062; Fig 5D) . Relative frequencies of Th1 and Th17 cells were trending down following LBS administration in both controls and MS patients (data not shown).
We did not observe a change in frequencies of na€ ıve CD4 or na€ ıve CD8 T cells, central memory CD4 T cells, effector memory CD4 T cells, or central memory CD8 T cells following LBS supplementation in our cohort. Next, we performed high-throughput eukaryotic digital gene expression RNA-Seq on CD4 T cells isolated from PBMCs of controls and MS patients. We did not observe a significant change in expression of pro-and anti-inflammatory cytokines in CD4 T cells following LBS administration in our cohort.
Changes in Monocytes Frequencies and Activation in Peripheral Blood
Next, we performed immune cell profiling of monocytes from healthy control and MS patients at the three time ANNALS of Neurology Fig 5E) . We observed a trend toward decreased frequency of inflammatory monocytes after LBS supplementation in controls (p 5 0.068; Fig 5E) . Discontinuation of LBS was associated with increased frequency of inflammatory monocytes in healthy controls (p 5 0.033; Fig 5E) . In healthy controls, we also observed decreased MFI of costimulatory marker CD80 on classical monocytes 1 IL-10 1 T cells, CD39 1 CD127 low CD25 high T cells, CD4 1 LAP 1 T cells, and effector memory CD8 T cells in healthy controls (HC) and multiple sclerosis patients (MS) at the indicated time points determined by Wilcoxon signed-rank test. *p < 0.05; #p < 0.1. FACS analysis was used to compare (E,F) frequencies of intermediate monocytes, inflammatory monocytes, as well as CD80 mean fluorescence intensity (MFI) on classical monocytes and HLA-DR MFI on dendritic cells in HC and MS patients at the indicated time points determined by Wilcoxon signed-rank test, *p < 0.05; **p < 0.01; #p < 0.1. The following markers were used for the lineage pool: CD3, CD14, CD16, CD19, CD20, and CD56. HLA-DR 5 human leukocyte antigen D related.
(p 5 0.035; Fig 5E) following administration of LBS. In MS patients, we observed decreased MFI of human leukocyte antigen (HLA) D related (HLA-DR) on myeloidderived dendritic cells (CD45
) following administration of LBS (p 5 0.0156; Fig 5F) . Of note, we did not observe a change in frequencies of B cells, natural killer cells, myeloid, or plasmacytoid dendritic cells following administration of LBS in our cohort.
Gene Expression Profiling of Peripheral Monocytes
Next, we performed gene expression profiling in monocytes isolated from PBMCs of controls and MS patients using Nanostring immunology panel to measure the expression of 568 immune-related genes. We found decreased expression of MS risk allele HLA.DQA1 (p 5 0.011) as well as decreased expression of proinflammatory genes HLA.DPA1 (p 5 0.055) and IL6ST (p 5 0.0039) in monocytes following LBS administration in controls (Fig 6A) . In controls, we found increased expression of HLA.DPA1 as well as MS risk allele HLA.DPB1 following discontinuation of LBS (p 5 0.0078 and p 5 0.039, respectively; Fig 6A) . We found decreased expression of anti-inflammatory gene PTNP2 following discontinuation of LBS in controls (p 5 0.0078; Fig  6A) . Of note, we continued to observe decreased expression of IL6ST following discontinuation of LBS (p 5 0.039; Fig  6A) . We also continued to observe a trend toward decreased expression of HLA.DQA1 following LBS cessation (p 5 0.097; Fig 6A) .
We found increased expression of antiinflammatory genes IL-10RA (p 5 0.031), LILRB2 (p 5 0.031), and CYBB (p 5 0.031) as well as decreased expression of proinflammatory genes MALT1 (p 5 0.031) and LGALS3 (p 5 0.031) in monocytes following administration of LBS in MS patients (Fig 6A) . Expression of the CYBB gene remained decreased upon cessation of LBS (p 5 0.031; Fig 6A) . We also observed a trend toward decreased expression of LILRB2 following LBS discontinuation (p 5 0.094; Fig 6A) .
Thus, consistent with the findings from the FACS analysis showing that LBS administration was associated with decreased activation of monocytes as well decreased frequency of proinflammatory monocytes in controls and MS patients, at the transcriptomic level, we found decreased expression of proinflammatory genes in monocytes following LBS administration.
Correlations Between Gut Microbiota and Immune Markers in Peripheral Blood
Next, we investigated potential associations between gut microbiota and immune changes. We correlated microbial abundance with a set of immune markers that were significantly changed following LBS administration. Given that most immune markers and microbial abundance changes were observed following LBS administration, we focused on that time point for our correlation studies. We found a negative correlation between CD80 MFI on classical monocytes and relative abundance of the following five Streptococcus OTUs: NR0 (p 5 0.0029), NR624 (p 5 0.0057), NR552 (p 5 0.02), 536866 (p 5 0.028), and NR985 (p 5 0.0498) in controls (Fig 6B) . Decreased level of expression of HLA.DPA1 and HLA.DPB1 in monocytes was associated with increased relative abundance of the following three Lactobacillus OTUs: 304724 (p 5 0.026 and p 5 0.00579, respectively), 288784 (p 5 0.0091 for HLA.DPB1), and 316515 (p 5 0.021 and p 5 0.0107, respectively) in controls (Fig 6B) . We observed a negative correlation between relative abundance of Bifidobacterium OTU 4426298 and level of expression of HLA.DPA1 and HLA.DPB1 in monocytes from controls (p 5 0.02 and p 5 0.021, respectively; Fig 6B) . Bifidobacterium NR847 had a negative correlation with MFI CD80 on monocytes in controls (Fig 6B) . In controls, Bifidobacterium OTU 1142029 had a positive correlation with MFI CD80 and IL6ST (p 5 0.03 and p 5 0.043, respectively; Fig 6B) . In MS, OTU 1142029 had a positive correlation with anti-inflammatory gene CYBB (p 5 0.033). Thus, OTU 1142029 was associated with proinflammatory immune markers in controls and with an antiinflammatory marker in MS patients.
In MS, we found a trend toward a negative correlation between the following two Lactobacillus OTUs: 316515 and 304724 (p 5 0.066 and p 5 0.066, respectively) and MFI of HLA-DR on dendritic cells (Fig 6C) . CYBB had a negative correlation with the following two Streptococcus OTUs: 4424239 (p 5 0.033) and 4425214 (p 5 0.033) in MS patients (Fig 6C) . We found a trend toward a positive correlation between Streptococcus NROTU0 and LILRB2 in MS patients (p 5 0.058; Fig  6C) . Hence, Lactobacillus, Streptococcus, and Bifidobacterium genera that were enriched in the gut of controls and MS patients following LBS supplementation had a negative correlation with proinflammatory and a positive correlation with anti-inflammatory immune markers.
Correlations Between Stool Metabolites and Immune Markers in Peripheral Blood
We correlated stool metabolites concentration with a set of immune markers that were significantly changed following LBS administration. In controls, we observed that hypoxanthine had a negative correlation with HLA.DPA1 and HLA.DPB1 and a positive correlation with PTPN2 (p 5 0.0020, p 5 0.031, and p 5 0.037, respectively; Table  2 ). Of note, we mentioned above that hypoxanthine had a 
Discussion
Our studies showed that LBS supplementation was associated with an enrichment of taxa depleted in MS, including genus Lactobacillus in both controls and MS patients. We also observed a depletion of taxa associated with dysbiosis in MS such as genera Blautia and Dorea. In addition, LBS administration was also associated with a decreased in abundance of KEGG pathways implicated in MS, including methane metabolism, ABC transporters, Carbon fixation pathways in prokaryotes, as well as Porphyrin and chlorophyll metabolism. We found changes in stool metabolomics profile following LBS administration. Notably, increased levels of Lactobacillus OTU 304724 were associated with increased level of stool hypoxanthine level, which was associated with decreased expression of MS risk allele HLA.DPB1 as well as HLA.DPA1.
At the immune level, LBS effect was predominantly observed on monocytes and dendritic cells. LBS administration induced an anti-inflammatory peripheral immune response characterized by decreased frequency of intermediate monocytes in MS patients as well as decreased MFI of costimulatory marker CD80 on monocytes and a trend toward decreased frequency of inflammatory monocytes in controls. Administration of LBS was also associated with decreased MFI of HLA-DR on dendritic cells in MS subjects. In controls, gene expression studies in monocytes revealed decreased expression of proinflammatory genes, including MS risk alleles HLA.DQA1 and HLA.DBP1, following LBS supplementation. Similarly, in MS patients, we observed decreased expression of proinflammatory genes MALT1 and LGALS3 in monocytes following LBS administration. On the other hand, discontinuation of LBS had the opposite effect on peripheral immune function. Lactobacillus, Streptococcus, and Bifidobacterium genera had a negative correlation with the following proinflammatory immune markers: CD80 MFI on classical monocytes, MFI HLA-DR on dendritic cells, and expression of HLA.DPA1 and HLA.DPB1 on monocytes.
Although our study provides initial insights into understanding the potential role for probiotics in the management of MS, our study has certain limitations.
The small sample size may have precluded the detection of other important differences.
Given our limited sample size, the minimum attainable p value for the Wilcoxon signed-rank test for the comparison of baseline to on probiotics was 0.0039, and this p value was attained for several of the OTUs. When we corrected for multiple comparisons using the FDR, none of the OTUs were significant when controlling the FDR at 0.05, but this was attributed to the limit on the minimum attainable p value from our sample size. For this reason, we did not calculate FDR for stool metabolomics, FACS, gene expression studies, and correlations studies. Also, patients were stable and on treatment, which may have made it difficult for us to observe the full anti-inflammatory potential of LBS.
However, the study has several strengths, including the relative homogeneity of MS cases, the exclusion of conditions that can affect the gut microbiome, and the fact that, by study design, each individual served as their own control. Of note, the probiotic effect was similar in both groups despite the age and body mass index differences.
Despite the study's small size, our results have important implications. First, that high-dose probiotic supplementation is safe and well tolerated by MS patients taking glatiramer acetate. Second, that LBS supplementation can reverse MS-induced alterations in the gut microbiota composition and function. Third, that probiotic LBS-induced changes in the gut microbiome are associated with an antiinflammatory peripheral immune response in controls and MS subjects. Hence, these findings suggest that LBS could have a synergistic effect with current MS diseasemodifying therapies. Of note, most of the LBS-induced changes in the gut microbiome and peripheral immune system did not persist following discontinuation of LBS, thereby implying that probiotic supplementation will need to be done continuously. This study is the first report on the effect of LBS on the gut microbiome and peripheral immune function in the context of MS. This study is a proof-of-principle study to investigate whether it is possible to modulate the gut microbiome of MS patients by using probiotics. Given that all the gut microbiome studies so far were conducted in RRMS patients, we focused on that patient population. We also opted for a simple study design in which all patients were on a single diseasemodifying drug (DMD) and we chose glatiramer acetate. It must be emphasized that we have no information on the long-term safety of LBS in the MS population and do not know whether the beneficial changes in the gut and immune system will be maintained in MS patients who are on LBS for a long period of time. Additional studies are required to evaluate the long-term safety and immunomodulatory properties of LBS in both relapsing-remitting and progressive MS patients as well as in patients on different types of DMDs. Such studies will help determine whether there are synergistic effects of LBS with certain DMDs and not with others. In addition, it will also be important to determine whether LBS-induced anti-inflammatory peripheral immune responses are associated with improved clinical outcome in MS patients.
